Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of SPH6516 Tablets in Subjects With Advanced Solid Tumors.

Next Previous
Trial Profile

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of SPH6516 Tablets in Subjects With Advanced Solid Tumors.

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 23 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs I 022 K (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Shanghai Pharmaceutical Group

Most Recent Events

  • 19 Feb 2024 Status changed from recruiting to completed.
  • 09 May 2022 New trial record
  • 20 Jan 2022 According to a Shanghai Pharmaceutical Group media release, this study is currently being conducted in a number of research centers headed by Sun Yat-Sen University Cancer Hospital.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top